drugset / Trial / NCT00003427
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
Phase 1
Completed
36 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of oxaliplatin plus irinotecan in treating patients with previously treated metastatic gastrointestinal cancer that has not responded to previous treatment.
Timeline
- Start
- 1998-04
- Primary completion
- 2002-04
- Completion
- 2002-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 40 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 60 mg/m2 | Intravenous |